TAA-specific CTLs- fixed dose

Phase 1

BBaylor College of Medicine

TAA-specific CTLs- fixed dose is one of 38 therapeutic programs targeting Multiple Myeloma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Multiple MyelomaActive, not recruiting

Multiple MyelomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

282 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 3

17 2

Xpovio

KKaryopharm Therapeutics Inc

Phase 3

29 3

Opdivo

Bristol-Myers Squibb

Phase 3

11 4

Treanda

AAzurity Pharmaceuticals

Phase 3

19 5

Neulasta

Amgen

Phase 3

5 6

Vepesid

AAvyxa

Phase 3

17 7

Busulfex

Akero Therapeutics

Phase 3

15 8

BLENREP

GGlaxo Dba Glaxosmithkline

Phase 3

10 9

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

9 10

Mezigdomide

Bristol-Myers Squibb

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Active, not recruiting

Multiple Myeloma

NCT02291848

Clinical

Trials by Indication[1]

Multiple Myeloma1 trial

Administration of Tumor-Associated Antigen (TAA)-Specific Cytotoxic T-Lymphocytes to Patients With Active Myeloma (TACTAM)

Active, not recruiting·BBaylor College of Medicine·Phase 1·NCT02291848·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for TAA-specific CTLs- fixed dose. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for TAA-specific CTLs- fixed dose. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Baylor College of Medicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: BBaylor College of Medicine

TAA-specific CTLs- fixed dose

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Multiple Myeloma1 trial

References

Drug Info

Quick Facts

Related News